MedPath

Fitostimoline® Hydrogel Versus Saline Gauze Dressing in Diabetic Foot Ulcers

Phase 4
Completed
Conditions
Diabetic Foot
Interventions
Drug: Saline gauze group
Drug: Fitostimoline ® hydrogel group
Registration Number
NCT05661474
Lead Sponsor
Federico II University
Brief Summary

Diabetes Mellitus (DM) is one of the most widespread metabolic diseases and the alarming rise in its prevalence worldwide poses enormous challenges. The microvascular and macrovascular complications of DM heavy impact on longevity and quality of life, and in particular diabetic foot ulcers (DFUs) are among the ten top causes of worldwide disease burden and disability Essential components of the standard care, management, and treatment of DFUs are represented by health education, strict control of blood glucose and cardiovascular risk factors, offloading, local debridement, and adequate dressing. A wide variety of dressing is available, and these include basic contact dressings (low adherence dressings such as saline gauze, paraffin gauze or simple absorbent dressings) and advanced dressings (alginate, hydrogel, films, hydrocolloid, foam).

It is important underline that due to lack of evidence from head-to-head randomized controlled trials (RCTs), the relative effects of any of these dressings in DFUs remain unclear. Consequently, so far clinical evidence supporting the choice for either hydrogel or saline gauze dressing, has been related mostly on clinician perception rather than high quality evidence. Here we evaluated the efficacy and safety of Fitostimoline® hydrogel dressing versus saline gauze dressing in patients with DFUs in a monocentric, two-arm, open-label, randomized, controlled trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Type 1 diabetes and type 2 diabetes,
  • adult patients with DFUs at Grades IC or IIC for a period of at least 12 weeks,
  • an akle brachial index >0.8,
  • be able to understand simple instructions,
  • provided voluntary, signed informed consent
Exclusion Criteria
  • active infection
  • evidence of ischaemia in the limb,
  • osteomyelitis,
  • gangrene,
  • systemic inflammatory or autoimmune disease,
  • use of corticosteroids, immunosuppressive agents, radiation therapy and chemotherapyan,
  • known hypersensitivity to any of the dressing components.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saline gauze groupSaline gauze groupParticipant randomized to the Saline gauze group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied saline gauze, finally the wound was covered with gauze.
Fitostimoline® hydrogel groupFitostimoline ® hydrogel groupParticipant randomized to the Fitostimoline® hydrogel group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied Fitostimoline ® hydrogel, finally the wound was covered with gauze.
Primary Outcome Measures
NameTimeMethod
the proportion of patients complete responders12 weeks

The primary outcome was the proportion of patients that at the end of study period of 12 weeks (V6) were categorized as complete responders -complete healing of the wound defined as reepithelialisation of 100% without medications.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Clinical Medicine and Surgery Federico II University

🇮🇹

Naples, Italy

© Copyright 2025. All Rights Reserved by MedPath